Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Non-Current Liabilities (2017 - 2020)

Historic Other Non-Current Liabilities for Vistagen Therapeutics (VTGN) over the last 7 years, with Q4 2020 value amounting to $5.9 million.

  • Vistagen Therapeutics' Other Non-Current Liabilities rose 2640.46% to $5.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was $5.9 million, marking a year-over-year increase of 2640.46%. This contributed to the annual value of $5.0 million for FY2020, which is N/A changed from last year.
  • Per Vistagen Therapeutics' latest filing, its Other Non-Current Liabilities stood at $5.9 million for Q4 2020, which was up 2640.46% from $5.7 million recorded in Q3 2020.
  • Over the past 5 years, Vistagen Therapeutics' Other Non-Current Liabilities peaked at $5.9 million during Q4 2020, and registered a low of $1.8 million during Q2 2017.
  • For the 4-year period, Vistagen Therapeutics' Other Non-Current Liabilities averaged around $3.8 million, with its median value being $3.5 million (2018).
  • Per our database at Business Quant, Vistagen Therapeutics' Other Non-Current Liabilities surged by 5789.82% in 2018 and then skyrocketed by 2640.46% in 2020.
  • Quarter analysis of 4 years shows Vistagen Therapeutics' Other Non-Current Liabilities stood at $2.3 million in 2017, then soared by 47.43% to $3.5 million in 2018, then surged by 35.59% to $4.7 million in 2019, then rose by 26.4% to $5.9 million in 2020.
  • Its Other Non-Current Liabilities was $5.9 million in Q4 2020, compared to $5.7 million in Q3 2020 and $5.3 million in Q2 2020.